Objective To highlight the complications involved in interpreting laboratory tests of measles immunoglobulin M (IgM) for confirmation of infection during a measles outbreak in a highly vaccinated population after conducting a mass immunization campaign as a control measure. Methods This case study was undertaken in the Republic of the Marshall Islands during a measles outbreak in 2003, when response immunization was conducted. A measles case was defined as fever and rash and one or more of cough, coryza or conjunctivitis. Between 13 July and 7 November 2003, serum samples were obtained from suspected measles cases for serologic testing and nasopharyngeal swabs were taken for viral isolation by reverse transcriptase polymerase chain reaction (RT-PCR). Findings Specimens were collected from 201 suspected measles cases (19% of total): of the ones that satisfied the clinical case definition, 45% were IgM positive (IgM+) and, of these, 24% had received measles vaccination within the previous 45 days (up to 45 days after vaccination an IgM+ result could be due to either vaccination or wild-type measles infection). The proportion of IgM+ results varied with clinical presentation, the timing of specimen collection and vaccination status. Positive results on RT-PCR occurred in specimens from eight IgM-negative and four IgM+ individuals who had recently been vaccinated. Conclusion During measles outbreaks, limiting IgM testing to individuals who meet the clinical case definition and have not been recently vaccinated allows for measles to be confirmed while conserving resources.
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Introduction
To measure the success of a measles control programme, laboratory confirmation of suspected measles cases is essential. Current recommendations for laboratory confirmation of measles vary according to the phase of measles control in a region or country and to laboratory capacity. 1 In the early phase, cases are diagnosed clinically almost exclusively; the role of the laboratory is to confirm initial cases and to isolate and analyse wild-type virus strains from selected cases to characterize the genotype of circulating measles viruses (MVs).
As countries progress from measles control to elimination, case-based surveillance is recommended. This involves detailed case investigation and collection of key variables such as age, vaccination status and outcome of illness. At this phase, the role of the laboratory is to confirm measles cases, to monitor circulating MV genotypes and -in collaboration with epidemiologists -to monitor measles immunity levels in the population. WHO recommends that both case-based investigation and specimen collection should be discontinued when outbreaks occur in settings targeted for measles elimination. Instead, 5-10 clinical specimens for serologic and molecular epidemiologic testing should be collected at the beginning of the outbreak to confirm MV as the etiologic agent and genetically characterize the virus. Clinical specimens should also be collected at 2-3-week intervals from each new chain of transmission until the outbreak is controlled.
Many countries in resource-poor settings are rapidly advancing towards measles elimination and are collecting specimens from all cases for investigation in the laboratory. In spite of the recommendations, there is still an emphasis on investigating and obtaining laboratory samples from all cases in an outbreak. 2, 3 This approach can drain existing funds and human resources and divert attention away from effective outbreak control measures.
Labnet International, Inc. (Labnet) -a WHO global measles/rubella laboratory network comprising about 700 laboratories -has been established to support measles surveillance. For confirmation of measles, Labnet has adopted the immunoglobulin M (IgM) enzyme immunoassay (EIA) performed on serum collected at first contact. 4, 5 The assay is reliable, sensitive and specific; however, IgM production and detection are affected by the vaccination status of suspected cases, the length of time since vaccination and the timing of specimen collection.
5 Confirmation of measles is also complicated by the use of outbreak response immunization (ORI) because, up to 45 days' post-vaccination, an IgM positive (IgM+) result could be due to either the vaccine or wild-type measles infection.
6
In 2003, the Republic of the Marshall Islands (RMI) (population 51 000) experienced a large measles outbreak. A total of 1122 reported rash illnesses were investigated, of which 1082 were from Majuro, the RMI capital. The RMI has used The RMI public health department initiated nationwide ORI activities and increased efforts to raise public awareness. At the same time, the department promoted active case finding and investigation of suspected measles cases by health-care providers and ensured that cases were managed appropriately. Based on the age distribution of reported cases, MMR vaccine was administered to persons aged 6 months to 40 years. Through the ORI, approximately 33 000 individuals (about 93% of the target population) were vaccinated.
The 2003 outbreak offered the opportunity to examine the performance of laboratory confirmation of IgM against MV during an outbreak in a highly vaccinated population where a mass immunization campaign was conducted as a control measure.
Methods
We used the WHO measles clinical case definition -fever and rash and one or more of cough, coryza or conjunctivitis -and applied this to residents of Majuro, RMI's most populous atoll (coral-reef island), between 13 July and 7 November 2003. A laboratoryconfirmed case was defined as a patient with serologic or virologic evidence of acute measles infection. Cases were investigated using a standardized datacollection form with demographic information, clinical features, vaccination history and outcome of illness. Vaccination history was obtained through parental or patient recall, personal and medical records, and immunization logs maintained by the local health department. Patients were classified as "vaccinated" if the recall or documentation provided the number or dates of their vaccinations; "no history of vaccine" if they reported receiving no measles vaccine and had no documentation of vaccination; and "unknown vaccination status" if such status was not known by patient history and there was no documentation of vaccination.
We collected serum for serologic testing and nasopharyngeal swabs for virus isolation and genetic characterization from a subset of suspected measles cases; however, the selection was not systematic and went beyond cases meeting the clinical case definition (Fig. 1) . Commonly, specimens were collected during the first medical contact and tested at the United States Centers for Disease Control and Prevention (CDC) for anti-measles virus IgM using established assays. 9 An IgM+ cut-off value was defined as a P−N > 0.09 and a P/N of > 3.0, with P representing the measured optical density values for MV antigen-containing wells, and N the optical density values for wells con- 
Met clinical case definition n = 826 (76%) Sera available n = 169 (84%) Among laboratory-tested cases that met the clinical-case definition, IgM results varied by timing of specimen collection, history of measles vaccination and time since MMR vaccination. Only 34% of sera were collected during the ideal collection period of 4-28 days after rash onset, while 50% were collected within 3 days of rash onset (Table 1) . Overall, regardless of vaccination history, the proportion of IgM+ results was highest when blood was collected 4-28 days after rash onset (60%) and lowest when it was collected within 3 days of rash onset (36%) (P = 0.007). When blood was collected 4-28 days after rash onset, 73% of individuals with no history of vaccination were IgM+, compared with only 39% (5/13) of individuals who had received at least one dose of vaccine. When specimens were obtained within 3 days of rash onset, only 40% (12/30) of individuals with no previous history of vaccination were IgM+. Of individuals who received one dose of measles vaccine, 71% (5/7) were IgM+ within 3 days of rash onset compared with 25% (1/4) of those sampled 4-28 days after rash onset. Among those who received at least two doses of vaccine, 44% (4/9) of those whose samples were collected in the 4-28-day period after rash onset were IgM+, compared with 8% (1/13) of those whose samples were obtained within 3 days (P = 0.048).
RT-PCR results were available for 38 suspected cases, of which 13 (34%) were positive for genotype H1 wildtype MV; no MV vaccine sequences were identified. Both RT-PCR and the results of serum tests were available for 27 suspected cases whose specimens had been collected mostly within 3 days of rash onset. IgM test and RT-PCR results were positive in four individuals that were thus confirmed as measles cases. Eight had positive results on RT-PCR but were IgM negative (IgM-). Thus, it was possible to confirm infection with wild-type measles virus in the laboratory despite a negative IgM test result (6 out of 8 cases had a positive vaccination history). Four specimens from individuals who received ORI showed amplified products bearing genotype H1 nucleotide sequences. Without these RT-PCR results, these individuals could not have been confirmed as cases.
Discussion
Our results confirm that the interpretation of serologic tests for the detection of IgM against the MV can be compromised in measles elimination settings with moderate to high levels of vaccine coverage, particularly where ORI activities are being conducted in response to a measles outbreak. We confirmed that the MV was the etiologic agent of the 2003 outbreak in the RMI by detecting IgM against the MV and MV RNA. 7 We also used limited testing (IgM EIA) to rule out other infectious agents (for rubella, dengue and parvovirus B-19) as the cause of the outbreak. However, most of the cases tested that met the clinical case definition and had a history of measles vaccination were IgM-. Individuals who did not meet the clinical case definition had extremely low rates of laboratory confirmation, irrespective of vaccination history, suggesting that efforts to confirm such cases through laboratory tests are not warranted.
Among cases that fit the clinical case definition, only 46% tested positive for IgM against the MV. Several factors could account for the high proportion of IgM-results. Blood collection outside the recommended time period may result in an IgM-test result because the individual may not have mounted a detectable IgM response.
11,12
Also, although the numbers are small, the data imply that vaccine recipients may mount a more rapid IgM response than unvaccinated individuals. In the latter, the IgM response may be either short-lived or absent; therefore, it may be missed even if serum is drawn during the optimal 4-28-day period after the onset of the rash. 6 The identification of eight vaccinated IgM-individuals in whom clinical evidence of measles infection was confirmed by RT-PCR and RNA sequencing supports these points. Finally, awareness of the measles outbreak may have led to a more liberal interpretation of the measles case definition, so that non-measles rash illnesses were reported as measles and serum specimens were then sent for laboratory testing. Due to ORI activities, 24% of IgM+ cases had received the MMR vaccine in the month before their illness. Measles cannot be confirmed by testing for IgM in cases vaccinated 45 days or less prior to blood collection because the antibody response to the vaccine mimics the response to wild-type virus infection.
13 MMR vaccination can lead to rash and fever but seldom causes cough, coryza and conjunctivitis. These individuals met the clinical case definition, which suggests they had measles rather than a vaccine reaction. The only way to clearly differentiate natural disease from a vaccine response in ORI recipients is to genetically characterize the MV involved through RNA detection and sequencing. During this outbreak, RT-PCR testing identified only wild-type measles virus, and not vaccine virus, as a cause of illness.
This study had limitations. Patients were selected for serum testing by convenience rather than by representative sampling of the outbreak population. Anecdotal reports from co-investigators suggested that many cases with mild symptoms were disproportionately selected for serum testing. When vaccination could not be documented, patient recall was accepted, although as a result the vaccinations actually received may have been under or overestimated.
14,15 Various studies show that parental recall of vaccination is less accurate than medical records 16, 17 and does not correlate well with protective antibodies measured in serum;
18 however, these studies were not conducted within 2 months of ORI activity in the midst of a measles outbreak.
Measles IgM testing in recently vaccinated individuals is inconclusive because a positive result could be due to either infection with the wild-type virus or to vaccination. The interpretation of IgM-results in distantly vaccinated cases is also challenging. Our findings that some of these cases were positive for MV RNA on RT-PCR suggest that in vaccinated individuals it may not be appropriate to rule out measles on the basis of an IgM-test result, especially if specimens were collected outside the optimal time window. Alternative laboratory diagnostic tools are needed for confirmation of measles in settings with high vaccination coverage; however, such tests would currently be beyond the scope of most Labnet facilities.
Our findings suggest that serologic IgM testing -although effective as a tool for confirming the etiologic agent causing outbreaks -has limited use in highly vaccinated populations, particularly in outbreak settings where ORI is being conducted. The situation seen in the RMI in 2003 will be encountered more frequently in the future as countries move towards measles elimination and ORI is more often used to control outbreaks.
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In measles-elimination settings, every suspected measles case must be fully investigated to understand whether actual cases are due to importation or to re-introduction of circulating virus in an under-immunized population. This information can then be used to manage immunization programmes. However, in practice it is not clear when to change from case-based investigation to outbreak investigation during an outbreak in such settings. In recent published accounts of measles outbreaks, case-based and laboratory investigations were conducted for more than 5-10 outbreak-related cases Objetivo Poner de relieve la complejidad de la interpretación de las pruebas de laboratorio de determinación de la inmunoglobulina M (IgM) del sarampión como confirmación de la infección en el contexto de un brote de esa enfermedad en una población altamente vacunada tras llevar a cabo una campaña de inmunización masiva como medida de control. Métodos El estudio se llevó a cabo en la República de las Islas Marshall durante un brote de sarampión registrado en 2003, año en que se emprendieron actividades de inmunización de respuesta. Se consideró definitorio de los casos de sarampión la presencia de fiebre, exantema y uno o más de los tres signos siguientes: tos, catarro o conjuntivitis. Entre el 13 julio y el 7 de noviembre de 2003 se obtuvieron muestras de suero de casos sospechosos de sarampión para realizar pruebas serológicas y se practicaron frotis nasofaríngeos para aislar el virus mediante la reacción en cadena de la polimerasa con transcriptasa inversa (RT-PCR).
Resultados Se obtuvieron muestras de 201 casos sospechosos de sarampión (19% del total): entre los que satisfacían la definición de caso clínico, el 45% fueron IgM-positivos (IgM+), y de éstos el 24% habían recibido vacunación antisarampionosa en los últimos 45 días (hasta 45 días después de la vacunación la IgM puede ser positiva como consecuencia ya sea de la vacunación o de una infección por el virus salvaje del sarampión). La proporción de resultados IgM+ varió según las manifestaciones clínicas iniciales, el momento de obtención de la muestra y el estado de vacunación. La RT-PCR dio resultados positivos en las muestras de ocho personas IgM-negativas y cuatro IgM-positivas que habían sido vacunadas recientemente. Conclusión Durante los brotes de sarampión es posible confirmar los casos de la enfermedad y ahorrar recursos si las pruebas de IgM se restringen a las personas que cumplen la definición de caso clínico y no han sido vacunadas recientemente. 
